Spencer promotes blood flow imaging device

Article

Spencer Technologies of Seattle has filed a 510(k) with the FDA to market a new transcranial Doppler device: a noninvasive combination of hardware and software that helps clinicians image and track blood flow with ultrasound. The company is

Spencer Technologies of Seattle has filed a 510(k) with the FDA to market a new transcranial Doppler device: a noninvasive combination of hardware and software that helps clinicians image and track blood flow with ultrasound.

The company is developing five proprietary Doppler ultrasound products addressing the detection, prevention, and treatment of conditions leading to stroke, pulmonary embolism, deafness, and cranial hemorrhage. The transcranial Doppler technology is designed to help diagnose conditions that may lead to stroke, according to the firm.

Spencer Technologies president and CEO Scott Seidel said customers will replace older analog ultrasound technology with this product.

Some ultrasound systems use harmonic imaging to visualize blood activity. The difference between transcranial Doppler and harmonic imaging is that the former images blood flow, while the latter visualizes the outline of blood vessels, Seidel said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.